EcoDrugPlus

Phosphodiesterase 4a

Ensembl ID : ENSPKIG00000016008
Gene Symbol: PDE4A
1 Cross references
197 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSPKIG00000014217
Gene Symbol: PDE4B
3 Cross references
299 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSPKIG00000019035
Gene Symbol: PDE4B
4 Cross references
154 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSPKIG00000018391
Gene Symbol: PDE4D
3 Cross references
235 Possible Orthologues:

Phosphodiesterase 5a, Cgmp-Specific, B

Ensembl ID : ENSPKIG00000016389
Gene Symbol: PDE5AB
1 Cross references
223 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSPKIG00000017477
Gene Symbol: PDE7A
4 Cross references
180 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSPKIG00000023116
Gene Symbol: PDE7B
4 Cross references
189 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSPKIG00000003345
Gene Symbol: PDE9A
1 Cross references
186 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSPKIG00000018561
Gene Symbol: PIK3R1
1 Cross references
53 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSPKIG00000025579
Gene Symbol: PIK3R1
3 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSPKIG00000006516
Gene Symbol: PIK3R2
1 Cross references
191 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSPKIG00000010834
Gene Symbol: PIK3R3
3 Cross references
243 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).